Cardio-Renal Advisory Committee
will review Marion's Cardizem SR (diltiazem, sustained release) and Syntex' Cardene (nicardipine) for hypertension, and Lilly's indecainide and Ciba-Geigy's Lopressor (metoprolol) for arrhythmias at its Nov. 3-4 meeting, according to draft agenda.
You may also be interested in...
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.
England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”